Involvement of reactive oxygen species/c-Jun NH2-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells

被引:41
作者
Kuo, Po-Lin [1 ]
Chen, Chung-Yi [2 ]
Tzeng, Tz-Fei [3 ]
Lin, Chun-Ching [3 ,4 ]
Hsu, Ya-Ling [1 ]
机构
[1] Chia Nan Univ Pharm & Sci, Dept Biotechnol, Cell Biol Lab, Tainan, Taiwan
[2] Fooyin Univ, Sch Med & Hlth Sci, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Coll Pharm, Fac Pharm, Kaohsiung, Taiwan
关键词
kotomolide A; apoptosis; ROS; JNK; breast cancer;
D O I
10.1016/j.taap.2008.01.034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The anticancer effects of kotomolide A (KTA), a new butanolide constituent isolated from the leaves of Cinnamomum kotoense (Lauraceae), on the two human breast cancer cell lines MCF-7 and MDA-MB-231, were first investigated in our study. KTA exhibited selectively antiproliferative effects in cancer cell lines without showing any toxicity in normal mammary epithelial cells. Treatment of cancer cells with KTA to trigger G2/M phase arrest was associated with increased p21/WAF1 levels and reduced amounts of cyclin A, cyclin B1, cdc2 and cdc25C. KTA induced cancer cell death treatment by triggering mitochondrial and death receptor 5 (DR5) apoptotic pathways, but did not act on the Fas receptor. Exposure of MCF-7 and MDA-MB-231 cells to KTA resulted in cellular glutathione reduction and ROS generation, accompanied by JNK activation and apoptosis. Both antioxidants, NAC and catalase, significantly decreased apoptosis by inhibiting the phosphorylation of JNK and subsequently triggering DR5 cell death pathways. The reduction of JNK expression by siRNA decreased KTA-mediated Bim cleavage, DR5 upregulation and apoptosis. Furthermore, daily KTA i.p. injections in nude mice with MDA-MB-231 s.c. tumors resulted in a 50% decrease of mean tumor volume, compared with vehicle-treated controls. Taken together, the data show that cell death of breast cancer cells in response to KTA is dependent upon ROS generation and JNK activation, triggering intrinsic and extrinsic apoptotic pathways. The ROS/JNK pathway could be a useful target for novel approaches in breast cancer chemotherapy. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:215 / 226
页数:12
相关论文
共 35 条
[1]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]  
BARGE J, 2001, NAT MED, V7, P548
[3]   Gene structure, alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim [J].
Bouillet, P ;
Zhang, LC ;
Huang, DCS ;
Webb, GC ;
Bottema, CDK ;
Shore, P ;
Eyre, HJ ;
Sutherland, GR ;
Adams, JM .
MAMMALIAN GENOME, 2001, 12 (02) :163-168
[4]   Cell cycle control in breast cancer cells [J].
Caldon, CE ;
Daly, RJ ;
Sutherland, RL ;
Musgrove, EA .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (02) :261-274
[5]   Chemical and cytotoxic constituents from the leaves of Cinnamomum kotoense [J].
Chen, Ching-Hsein ;
Lo, Wen-Li ;
Liu, Ya-Chen ;
Chen, Chung-Yi .
JOURNAL OF NATURAL PRODUCTS, 2006, 69 (06) :927-933
[6]  
FEIG DI, 1994, CANCER RES, V54, pS1890
[7]   Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis [J].
Filomeni, G ;
Aquilano, K ;
Rotilio, G ;
Ciriolo, MR .
CANCER RESEARCH, 2005, 65 (24) :11735-11742
[8]   CELLULAR TUMORIGENICITY IN NUDE MICE - CORRELATION WITH CELL-GROWTH IN SEMISOLID MEDIUM [J].
FREEDMAN, VH ;
SHIN, S .
CELL, 1974, 3 (04) :355-359
[9]   Thioredoxin and protein kinases in redox signaling [J].
Fujino, Go ;
Noguchi, Takuya ;
Takeda, Kohsuke ;
Ichijo, Hidenori .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) :427-435
[10]   Ginsenoside-Rh2-induced mitochondrial depolarization and apoptosis are associated with reactive oxygen species-and Ca2+-mediated c-Jun NH2-terminal kinase 1 activation in HeLa cells [J].
Ham, Young-Mi ;
Lim, Jin-Hee ;
Na, Hye-Kyung ;
Choi, Joon-Seok ;
Park, Byoung-Duck ;
Yim, Hyungshin ;
Lee, Seung-Ki .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :1276-1285